Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05152186
Other study ID # blood loss in spine surgery
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date June 1, 2021
Est. completion date December 1, 2021

Study information

Verified date December 2021
Source Minia University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the effectiveness of topical TXA in reducing blood loss compared to H2O2 wash. The primary outcomes : 1. Estimation of Intraoperative blood loss and blood transfusion. 2. Recording Postoperative blood drainage. 3. Comparing Hemoglobin levels (pre and postoperative). The secondary outcomes : 1. Surgical site infection (SSI) 2. Length of hospital stay.


Description:

Spinal surgery is one of the most commonly performed neuro-surgeries worldwide. Massive blood loss occurs frequently and remains a challenge in complex spinal surgery. Significant intra and postoperative hemorrhage negatively affects patient outcomes by increasing coagulopathy, postoperative hematoma and anemia .The need for allogenic blood transfusions can lead to potential transfusion reactions and infections, in addition to increasing long-term mortality rates. There is an economic disadvantage associated with iatrogenic major blood loss relating to the direct costs of the blood products and intraoperative blood salvage technology and indirect costs of prolonged patient hospitalization and complication management . Many efforts have focused on achieving better perioperative blood conservation, in particular through prophylactic intravenous administration of antifibrinolytic agents before and during major surgery. Intravenous administration of the inexpensive but highly effective drug as tranexamic acid (TXA) reduces perioperative hemorrhage and the need for blood transfusions by one third in major surgery, including spinal surgery, Included on the list of the World Health Organization (WHO) List of Essential Medicines, TXA has taken its place as a widely used hemostatic agent in the clinical setting . Tranexamic acid is a synthetic analog of the amino acid lysine. It serves as an antifibrinolytic by reversibly binding four to five lysine receptor sites on plasminogen. This reduces conversion of plasminogen to plasmin, preventing fibrin degradation and preserving the framework of fibrin's matrix structure .Tranexamic acid has roughly eight times the antifibrinolytic activity of an older analogue, ε-aminocaproic acid. Tranexamic acid also directly inhibits the activity of plasmin with weak potency . Hydrogen peroxide (H2O2) is an inexpensive and readily available option whose hemostatic and antiseptic properties have been separately confirmedin several previous studies .


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 120
Est. completion date December 1, 2021
Est. primary completion date November 1, 2021
Accepts healthy volunteers No
Gender All
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria: - ASA: class II or III - Sex: male and female - Age: from 20 to 70 years. - Type of operation: patient will undergo spinal surgery with a diagnosis of in place spinal trauma, thoracic or lumbar degenerative disease, such as spinal canal stenosis, disc herniation, spondylolisthesis, and/or degenerative scoliosis under general anesthesia. Exclusion Criteria: - Patients with history of thromboembolic disease or coagulopathy or hereditary bleeding disorders such as factor VIII deficiency, factor IX deficiency, and Von-Willebrand disease. - Patients who were taking anticoagulants or antiplatelet drugs. - Allergy or hypersensitivity to TXA. - A dural tear accompanied by cerebrospinal fluid leakage detected intraoperatively. - Spinal cord tumors, head trauma and penetrating spinal cord trauma. - The use of intravenous TXA during the perioperative period . - Infection at the operative site e.g T.B.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Topical Solution
Topical administration
Topical Foam
Topical administration
Other:
Topical
Topical administration

Locations

Country Name City State
Egypt Minia University hospital Minya

Sponsors (1)

Lead Sponsor Collaborator
Minia University

Country where clinical trial is conducted

Egypt, 

References & Publications (2)

Hui S, Peng Y, Tao L, Wang S, Yang Y, Du Y, Zhang J, Zhuang Q; TARGETS study group. Tranexamic acid given into wound reduces postoperative drainage, blood loss, and hospital stay in spinal surgeries: a meta-analysis. J Orthop Surg Res. 2021 Jun 22;16(1):401. doi: 10.1186/s13018-021-02548-6. — View Citation

Qureshi R, Puvanesarajah V, Jain A, Hassanzadeh H. Perioperative Management of Blood Loss in Spine Surgery. Clin Spine Surg. 2017 Nov;30(9):383-388. doi: 10.1097/BSD.0000000000000532. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Blood loss estimation [NCT ID not yet assigned] Estimation of perioperative blood loss and need of blood transfusion, lab investigations pre and postoperative (hemoglobin (gm/dL), hematocrit (%), Prothrombin concentration (%), INR, platelets).
Recording Postoperative blood drainage (in ml). and Comparing Hemoglobin levels (pre and postoperative).
Within 48 hours
Secondary Complications Anaemia secondary to blood loss, surgical site infection , length of hospital stay (in days), complications of drugs used in procedure. 7 days
See also
  Status Clinical Trial Phase
Completed NCT04588350 - Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery N/A
Completed NCT05426564 - Exploratory Assessment of the Quantra® System in Adult ECMO Patients
Active, not recruiting NCT05492214 - The Effect of Time Window for Umbilical Cord Clamping During Cesareans on Offspring Hemoglobin and Maternal Blood Loss N/A
Withdrawn NCT05518279 - Early Administration Of Tranexamic Acid And Acute Blood Loss In Patients With Hip Fractures Phase 3
Enrolling by invitation NCT02910115 - Cooling the Uterus in C-section After Dysfunctional Labor N/A
Completed NCT02569658 - Investigation of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty N/A
Completed NCT01048658 - Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures Phase 4
Terminated NCT02908516 - Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures Phase 4
Completed NCT04089865 - Oral Versus Intravenous Tranexamic Acid Phase 4
Recruiting NCT06403163 - Transfusion Surveillance in Anaesthesia
Recruiting NCT02265562 - Rectal Misoprostol and Blood Loss During Abdominal Hysterectomy Phase 3
Completed NCT02083809 - Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation N/A
Completed NCT02312440 - Comparison of Topical and Intravenous Tranexamic Acid in Total Hip Arthroplasty Phase 3
Completed NCT01895101 - The Effect on Blood Loss of Topical and Intravenous Tranexamic Acid in Cardiac Surgery Patients Phase 4
Completed NCT01099475 - Effect of Intermittent Pedicle Clamping on Hepatocellular Injury During Liver Surgery N/A
Completed NCT00990288 - The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery Phase 4
Completed NCT03365999 - Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement. Phase 2
Recruiting NCT05550623 - Pneumatic Tourniquet Versus no Tourniquet in Transfemoral Amputation N/A
Completed NCT05012202 - Validating a New Point-of-care Device for Estimation of Blood Count in Pregnant Women
Completed NCT02311309 - Epidemiology of Severe Peroperative Bleeding During Scheduled Surgery N/A